Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD

Sponsor
University of Cologne
Study ID
NCT01213667
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
60 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ranibizumab — DRUG
    upload (three monthly injections), re-treatment as needed

Study Details

To assess genetic features and intraocular cytokine profiles of non-responders to anti-VEGF treatment of exudative age-related macular degeneration. Also to assess necessity and frequency of pro re nate medical re-treatment.

Key Dates

First listed
Oct 4, 2010
Start date
Jan 31, 2010
Status verified
Oct 2016
Primary completion
Dec 31, 2017
Completion
Dec 31, 2017

Study Design

Enrollment
110 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: ranibizumab as needed

Primary Outcome Measure

Visual acuity [ Time Frame: 2 years ]

Related Studies